

IX BIOPHARMA LTD.
(Company Registration No. 200405621W)
(Incorporated in the Republic of Singapore)

PROPOSED PLACEMENT OF 44,491,299 NEW ORDINARY SHARES IN THE CAPITAL OF IX BIOPHARMA LTD. – ALLOTMENT AND ISSUE OF SUBSCRIPTION SHARES

Unless otherwise defined, capitalised terms herein shall bear the same meanings as in the Company's announcements dated 28 July 2020, 20 August 2020, 27 August 2020, 28 August 2020, 4 September 2020 and 7 September 2020 in relation to the Proposed Placement (collectively, the "**Announcements**").

Further to the Announcements, the Directors wish to announce that 44,491,299 Subscription Shares were allotted and issued on 8 September 2020 by the Company on the terms and subject to the conditions set out in the Subscription Agreement. The issued and paid-up share capital of the Company has consequently increased to 693,385,689 Shares.

The Subscription Shares shall be free from all claims, charges, liens and other encumbrances and shall rank *pari passu* in all respects with and carry all rights similar to the existing Shares.

Due to a service outage of Bizfile, the business filing portal of the Accounting and Corporate Regulatory Authority ("**ACRA**"), on 8 and 9 September 2020, the filing of the Return of Allotment of Shares can only take place after the portal resumes service. The provision of the filed Return of Allotment of Shares is required by SGX-ST prior to crediting, listing and quotation of the Subscription Shares. While the Company continues to follow up closely with ACRA, the actual date of crediting, listing and quotation of the Subscription Shares will depend on the date that the Bizfile portal system issues are resolved.

Further announcements will be made to update on the expected date for the listing and trading of the Subscription Shares.

By Order of the Board

Lee Wei Hsiung / Wang Shin Lin, Adeline
Company Secretaries

9 September 2020

This announcement has been reviewed by the Company's sponsor, CIMB Bank Berhad, Singapore Branch (the "**Sponsor**"), in accordance with Rule 226(2)(b) of Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by SGX-ST and SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Yee Chia Hsing, Head of Catalist, CIMB Bank Berhad, Singapore Branch. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.